Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

JOINN Laboratories China Purchases Instem’s Preclinical Software Suite

Published: Wednesday, January 30, 2013
Last Updated: Wednesday, January 30, 2013
Bookmark and Share
Leading Chinese CRO selects Version 9 of Provantis integrated preclinical software to automate study processes at Beijing and Suzhou sites.

Instem, a leading provider of IT solutions to the global early development healthcare market, announced that JOINN Laboratories (JOINN), one of China’s largest providers of preclinical services, has purchased the Provantis preclinical solution suite following a comprehensive competitive evaluation of vendors.

Established in 1995, JOINN provides drug screening, efficacy studies, pharmacokinetics studies, safety evaluations, clinical trials and final drug registration services with a heightened focus on quality. JOINN supports clients from more than 20 provinces across China, Japan and Europe, and within the United States is providing international clients with technical consulting services for FDA drug registration.

Key facts
•    Comprehensive suite of integrated Provantis modules purchased for up to 200 users; including In-Life, Reproductive Toxicology, Pathology, Dispense, Clinical Pathology and Data Import
•    JOINN to implement Provantis 9; the latest version of Instem’s market leading preclinical software solution
•    Competitive evaluation conducted; Instem selected for established presence within China, combined with global market leadership
•    Provantis offers JOINN compliance to national and western standards with dual language operation
•    A range of professional services purchased to facilitate quicker, smoother implementation and faster return on investment

Dr. Yuxia Feng, President & CEO, JOINN commented “We were looking for a market leading solution to support our long term growth plans and we are confident that our investment in Provantis will help to deliver demonstrable efficiency improvements within our R&D facilities. We are looking forward to a long and successful partnership with Instem.”

Phil Reason, President & CEO Instem said “We are delighted to welcome JOINN to the Instem client community. Their order for 200 licensed users adds significantly to the leadership position we already enjoy in the China market and is a further indication of the long term growth potential in what is already the third largest pharmaceutical market in the world.”

As the first western toxicology/pathology software supplier to enter the Chinese market, Instem officially deployed its first China-based system in one of the largest and most advanced vivariums during 2006. Acknowledging analyst projections that the People’s Republic of China (PRC) is on pace to becoming the second largest pharmaceutical market in the world, Instem established a full-service office in Shanghai, recruited local staff and has localized the Provantis product suite into Mandarin Chinese. Instem is supporting international organizations and domestic laboratories exclusively serving the PRC using on-site systems as well as their SaaS delivery model from a professionally managed data center based in Shanghai.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
Crystal Clear Images Uncover Secrets of Hormone Receptors
NIH researchers gain better understanding of how neuropeptide hormones trigger chemical reactions in cells.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!